Michael C. Welsh

Presidente presso Almasa Capital, Inc.

81 anni

Health Services

Producer Manufacturing

Health Technology

Posizioni attive di Michael C. Welsh

Società	Posizione	Inizio	Fine
Almasa Capital, Inc.	Presidente	-	-

Società	Posizione	Inizio	Fine
CASCADIAN THERAPEUTICS INC (USA)	Direttore/Membro del Consiglio	01/03/1987	11/12/2008
Biomira, Inc. Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy	Direttore/Membro del Consiglio	01/01/1987	11/12/2007
Welsh & Co.	Corporate Officer/Principal	-	-
Micralyne, Inc. Micralyne, Inc. Industrial MachineryProducer Manufacturing Micralyne, Inc. develops and manufactures micro fabricated products. It offers wafer level packaging, die level packaging, silicon optical bench and spatial light valve. The firm’s services are used in the areas of microfluidics and MEMs sensors. The company was founded in 1982 and is headquartered in Edmonton, Canada.	Presidente	-	-

University of Alberta

Undergraduate Degree

Distribuzione geografica

Canada	5
Stati Uniti	3

Posizioni

Director/Board Member	2
Chairman	1
Corporate Officer/Principal	1

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	5
Biomira, Inc. Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy	Health Services
Micralyne, Inc. Micralyne, Inc. Industrial MachineryProducer Manufacturing Micralyne, Inc. develops and manufactures micro fabricated products. It offers wafer level packaging, die level packaging, silicon optical bench and spatial light valve. The firm’s services are used in the areas of microfluidics and MEMs sensors. The company was founded in 1982 and is headquartered in Edmonton, Canada.	Producer Manufacturing
Cascadian Therapeutics LLC Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA.	Health Technology
Welsh & Co.
Almasa Capital, Inc.